Skip to main content
. 2022 Feb 1;32(2):101252. doi: 10.1016/j.mycmed.2022.101252

Table 1.

. COVID-19 features in rhino-orbito-cerebral mucormycosis cases.

Case no Age/ Sex Month & Year Severity of COVID-19 † Remdesivir or Biological therapies Prednisolone Equivalent dose (mg) Diabetes DKA ‡ Hypertension Renal dysfunction ANC § (cells/mm3) ALC ¶ (cells/mm3) IL-6 †† (pg/ml) Serum Ferritin (ng/ml) D-Dimer Platelet count (x105 cells/mm3)
1 57/M November 2020 Mild – 0 + – + + 4592 2262 28.2 ND ‡‡ 180 3.79
2 67/M December 2020 Mild – 1000 + – + – 3795 900 45.4 682 650 3.78
3 70/M August 2020 Mild – 500 + – – – 4532 523 ND‡‡ ND‡‡ ND‡‡ 2.45
4 52/M September 2020 Mild – 937.5 + – – – 5148 726 ND‡‡ ND‡‡ ND‡‡ 1.98
5 60/M April 2021 Mild – 533.5 + – – + 8008 372 18.2 1500 4300 0.69
6 30/M April 2021 Moderate Remdesivir 1375 + (Denovo) + – + 17,520 1314 141.78 1500 1493 2.77
7 58/F April 2021 Mild – 0 + – + – 6500 1140 ND‡‡ 980 ND‡‡ 2.91
8 54/M May 2021 Severe Remdesivir 500 + (Denovo) – – – 7600 1120 1172 ND‡‡ 2965 1.38
9 47/M May 2021 Mild – 266 + (Denovo) – + – 6515 750 80.37 741 517 3.18
10 45/M May 2021 Mild – 550 + + – + 5762 603 ND‡‡ ND‡‡ ND‡‡ 1.55
11 56/M May 2021 Moderate Remdesivir 400 + – + – 6324 436 91.2 1080 780 1.45
12 61/F May 2021 Mild – 140 + – + – 9452 3475 ND‡‡ 374.5 296 2.42
13 25/M May 2021 Mild – 293 + (Denovo) + – + 1500 1136 ND‡‡ 1500 150 1.32
14 41/M May 2021 Mild Remdesivir 500 + – + – 3186 2014 ND‡‡ 804.9 200 1.98
15 56/M May 2021 Severe Remdesivir, Barcitinib 0 + – + – 3023 517 ND‡‡ 974 ND‡‡ 0.95
16 64/M May 2021 Moderate Remdesivir 550 + – + – 7390 1124 ND‡‡ 1320 ND‡‡ 3.3
17 46/M May 2021 Mild – 0 + – – + 6460 627 ND‡‡ ND‡‡ ND‡‡ 2.76
18 45/M May 2021 Severe Remdesivir 675 + (Denovo) – + – 8032 1160 118.5 242 868 1.22
19 48/M May 2021 Mild – 400 + – – – 7340 724 28.83 207.7 292 2.95
20 47/M May 2021 Moderate Remdesivir 625 + – + – 6790 1260 ND‡‡ ND‡‡ ND‡‡ 1.78
21 48/M May 2021 Severe – 563 + + – – 7905 425 266 1500 659 0.57
22 45/M May 2021 Severe Remdesivir 500 + – – + 4800 920 42 450 480 1.72
23 42/M May 2021 Mild – 100 + + + – 4000 900 ND‡‡ ND‡‡ ND‡‡ 1.5
24 56/M June 2021 Severe Remdesvir Bevacizumab 738 + + + + 4284 612 ND‡‡ 759 140 1.2
25 60/F June 2021 Severe Remdesivir 542 + + + + 5496 463 445.7 840.7 450 2.63
26 42/F May 2021 Mild – 480 + + – – 6240 735 32.5 743.5 234 1.67
27 38/M May 2021 Severe Remdesivir 1055.5 + – – – 2948 532 56.37 1056 260 1.33
28 33/M June 2021 Severe Remdesivir 627.5 + – – – 10,080 440 7.8 984 288 4.67
29 53/M June 2021 Mild – 0 + (Denovo) – – – 8946 975 54.7 ND‡‡ 210 2.45
30 69/M June 2021 Mild – 0 + – – – 7528 1432 ND‡‡ ND‡‡ ND‡‡ 2.67
31 70/M June-2021 severe Remdesivir 527 + + + + 13,072 1520 1004.88 ND‡‡ 889 1.20

† COVID-19: Corona virus disease 2019; ‡ DKA: Diabetic ketoacidosis; § ANC: Absolute neutrophil count; ¶ ALC: Absolute leukocyte count; †† IL-6: Interleukin 6; ‡‡ ND: Not done.